Morgan Stanley Bets on a UnitedHealth Beat — and Flags AI as the Hidden Upside

Morgan Stanley is making an early call ahead of healthcare earnings season: UnitedHealth Group (UNH) will likely top Wall Street’s second-quarter expectations. In a client note Tuesday, the firm pointed to favorable utilization trends and a strengthening operating story — and singled out artificial intelligence as an underappreciated profit lever the market hasn’t fully priced in.

A Beat in the Making

To start, Morgan Stanley estimates UnitedHealth will post adjusted earnings of $4.95 per share for the quarter, comfortably ahead of the $4.85 consensus. The firm credits favorable utilization trends, which bode well not just for UnitedHealth but for managed care organizations broadly as they prepare to report.

Crucially, the timing matters. UnitedHealth kicks off the sector’s earnings on July 16, and Morgan Stanley expects the insurer to “set a positive tone” for peers. Supporting that view, Humana (HUM) recently affirmed its guidance, while Ardent Health (ARDT) posted stronger year-on-year profitability despite softer seasonal volume — together pointing to what the firm called a more manageable utilization environment.

AI: The Underappreciated Driver

Beyond the quarter itself, Morgan Stanley argues that investors are overlooking a bigger story. The firm describes AI as an “underappreciated” earnings driver for UnitedHealth, which is investing $1.5 billion in artificial intelligence to save roughly $1 billion in operating costs in 2026.

Moreover, the firm views UnitedHealth as an “AI enabler” rather than just an adopter, with Optum Insight evolving into an AI-powered healthcare platform. As a result, Morgan Stanley estimates AI could drive about 20% EPS upside — and that’s before factoring in new high-margin insight revenue streams.

The Longer-Term Math

Looking further out, the firm projects 2026 adjusted EPS of $18.27, just shy of the Street’s $18.39, and 2027 EPS of $20.96, essentially in line with the market’s $20.94. However, Morgan Stanley sees meaningful room above those numbers: if UnitedHealth executes its margin recovery strategy and moves toward target profitability, earnings could run 22% higher than current estimates.

Backing that conviction, the firm raised its price target to $468 from $453 and reiterated an heavy rating.

The Bottom Line

Ultimately, Morgan Stanley is framing UnitedHealth as both a near-term beat candidate and a long-term AI-driven margin story. While the stock traded slightly lower on the day, the firm’s thesis is clear: favorable utilization sets up a strong July print, and an aggressive AI investment could unlock upside that Wall Street hasn’t yet rewarded. Investors will get their first real test on July 16.